findmyKOL
Clinical trialNCT05212532UnknownPhase 1Interventional

A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms

SponsorEOM PharmaceuticalsEnrollment40COVID-19 Acute Respiratory Distress SyndromeCOVID-19 PneumoniaCOVID-19 Respiratory Infection
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of EOM613, a peptide nucleic acid with novel immune-modulating properties, in treating patients with severe COVID-19 infections. This proof-of-concept study is the first clinical trial of EOM613 in this patient population.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Florentino Cardoso Filho, MD, PhD

    Physician, Casa de Saude Hospital, Campinas, SP

    Principal Investigator
    clinicaltrials.gov ↗
  • Frank L Douglas, PhD, MD

    Scientific Advisor & Chair of Scientific Advisory Board, EOM Pharma

    Study Director
    clinicaltrials.gov ↗
  • Irach Taraporewala, PhD

    CEO and Director, EOM Pharma

    Study Chair
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Brazil
  • Oswaldo Cruz

    Manguinhos, Rio de Janeiro, Brazil

    Elie Fiss, MD, PhD
    Recruiting
  • Hospital de Amor

    Barretos, São Paulo, Brazil

    César Maurício, MD
    Recruiting
  • Hospital Municipal de Barueri

    Barueri, São Paulo, Brazil

    Paulo Tierno, MD
    Recruiting
  • Casa de Saúde

    Boqueirão, São Paulo, Brazil

    Florentino Cardoso Filho, MD, PhD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

EOM613
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
9 Aug 2021
Primary completion
28 Feb 2022
Completion
30 Mar 2022
Last update posted
28 Jan 2022
Registered enrollment
40
Registry id
NCT05212532
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.